YH003 + toripalimab + nab-paclitaxel + gemcitabine

This is a four-drug combination regimen consisting of **YH003** (an anti-CD40 monoclonal antibody), **toripalimab** (a programmed death receptor-1 [PD-1] immune checkpoint inhibitor), **nab-paclitaxel** (a nanoparticle albumin-bound formulation of the microtubule inhibitor paclitaxel), and **gemcitabine** (a nucleoside analog and antimetabolite chemotherapeutic). YH003 is designed to activate antigen-presenting cells via CD40, enhancing T-cell mediated anti-tumor immunity. Toripalimab inhibits PD-1, blocking tumor-induced immune evasion. Nab-paclitaxel disrupts microtubules and is formulated to improve tumor delivery and reduce solvent-related toxicity. Gemcitabine interferes with DNA synthesis in proliferating tumor cells. This combination is under clinical investigation for use in advanced or metastatic solid tumors, particularly pancreatic cancer, aiming to leverage synergistic antitumor effects from immune activation and chemotherapy[3][2].

Other names

toripalimab-tpzinab-paclitaxelalbumin-bound paclitaxelgemcitabine hydrochloride